(405) Antiretroviral Supramolecular Prodrug Hydrogelators as Long-Acting Injectables
Introduction: Globally, 39.9 million people lived with human immunodeficiency virus (HIV) and 630,000 people died from HIV-related cases in 2023—the latter has dropped by 69% from its peak due to antiretroviral therapy (ART) [1]. But ART is not curative and requires lifelong adherence, which makes long-acting ART a critical subject to address. Despite their significance, nucleoside reverse transcriptase inhibitors (NRTIs) lack long-acting options due to their hydrophilicity, so we utilized supramolecular hydrogels that can sequester the drugs to drive its self-assembly and controlled release [2, 3].
Learning Objectives:
Upon completion, participant will comprehend the necessity of a long-acting therapeutic for HIV.
Participants will learn of supramolecular hydrogel's advantages as an LAI for hydrophilic drugs.
Participants will be able to understand the importance of the diverse HIV drugs upon completion.
